A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Top Cited Papers
Open Access
- 1 March 2017
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 54, 58-67
Abstract
No abstract availableKeywords
Funding Information
- Lockwood Group Inc
- AstraZeneca
This publication has 51 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- HLA-G and Immune Evasion in Cancer CellsJournal of the Formosan Medical Association, 2010
- Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisitedCytokine & Growth Factor Reviews, 2009
- A History of Cancer ChemotherapyCancer Research, 2008
- PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomataCancer, 2007
- Early History of Endoscopic Treatment of Bladder Tumors From Grunfeld's Polypenkneipe to the Stern-McCarthy ResectoscopeJournal of Endourology, 2006
- LEGACY OF EDWIN BEER: FULGURATION OF PAPILLARY BLADDER TUMORSJournal of Urology, 2005
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995
- Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity, 1995
- Effect of Bacillus Calmette-Guérin Infection on Transplanted Tumours in the MouseNature, 1959